AU2495200A - Compositions and methods for the treatment of tumor - Google Patents

Compositions and methods for the treatment of tumor

Info

Publication number
AU2495200A
AU2495200A AU24952/00A AU2495200A AU2495200A AU 2495200 A AU2495200 A AU 2495200A AU 24952/00 A AU24952/00 A AU 24952/00A AU 2495200 A AU2495200 A AU 2495200A AU 2495200 A AU2495200 A AU 2495200A
Authority
AU
Australia
Prior art keywords
tumor
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24952/00A
Inventor
Avi J. Ashkenazi
Kevin P. Baker
Audrey Goddard
Austin L. Gurney
Kenneth J. Hillan
Margaret Ann Roy
Colin K. Watanabe
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/en
Priority claimed from PCT/US1999/012252 external-priority patent/WO1999063088A2/en
Priority claimed from PCT/US1999/028313 external-priority patent/WO2000032221A2/en
Priority claimed from PCT/US1999/030911 external-priority patent/WO2000075316A1/en
Priority claimed from PCT/US2000/000219 external-priority patent/WO2000053753A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2495200A publication Critical patent/AU2495200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
AU24952/00A 1999-03-08 2000-01-06 Compositions and methods for the treatment of tumor Abandoned AU2495200A (en)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
PCT/US1999/005028 WO1999046281A2 (en) 1998-03-10 1999-03-08 Novel polypeptides and nucleic acids encoding the same
WOUS9905028 1999-03-08
WOUS9912252 1999-06-02
PCT/US1999/012252 WO1999063088A2 (en) 1998-06-02 1999-06-02 Membrane-bound proteins and nucleic acids encoding the same
US14103799P 1999-06-23 1999-06-23
US60141037 1999-06-23
US14304899P 1999-07-07 1999-07-07
US60143048 1999-07-07
US14569899P 1999-07-26 1999-07-26
US60145698 1999-07-26
PCT/US1999/028313 WO2000032221A2 (en) 1998-12-01 1999-11-30 Promotion or inhibition of angiogenesis and cardiovascularization
WOUS9928313 1999-11-30
PCT/US1999/030911 WO2000075316A1 (en) 1999-06-02 1999-12-20 Methods and compositions for inhibiting neoplastic cell growth
WOUS9930911 1999-12-20
PCT/US2000/000219 WO2000053753A2 (en) 1999-03-08 2000-01-05 Promotion or inhibition of angiogenesis and cardiovascularization
WOUS0000219 2000-01-05
PCT/US2000/000376 WO2000053755A2 (en) 1999-03-08 2000-01-06 Compositions and methods for the treatment of tumor

Publications (1)

Publication Number Publication Date
AU2495200A true AU2495200A (en) 2000-09-28

Family

ID=56289989

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24952/00A Abandoned AU2495200A (en) 1999-03-08 2000-01-06 Compositions and methods for the treatment of tumor

Country Status (2)

Country Link
AU (1) AU2495200A (en)
WO (1) WO2000053755A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001248840B2 (en) * 2000-04-21 2005-06-09 Fuso Pharmaceutical Industries, Ltd. Novel collectins

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2286843T3 (en) 1997-01-14 2007-12-01 Human Genome Sciences, Inc. 6 ALPHA AND 6 BETA RECEIVERS OF THE TUMOR NECROSIS FACTOR.
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
US7053190B2 (en) 1997-03-07 2006-05-30 Human Genome Sciences, Inc. Secreted protein HRGDF73
US6242419B1 (en) * 1999-03-25 2001-06-05 Genesis Research & Development Corporation Ltd. Compositions isolated from stromal cells and methods for their use
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU1915201A (en) * 1999-12-07 2001-06-18 Eli Lilly And Company Improving stability of flint through o-linked glycosylation
CA2390685C (en) * 2000-01-06 2008-04-22 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
GB0004576D0 (en) * 2000-02-25 2000-04-19 Oxford Glycosciences Uk Ltd Proteins
US20040141974A1 (en) * 2000-02-25 2004-07-22 Boyd Robert Simon Diagnostic and therapeutic methods
EP1666493A1 (en) * 2000-06-02 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids ancoding the same
MXPA03004551A (en) * 2000-11-22 2004-03-26 Immunex Corp Methods of using imxp-888 and imxp-888 antagonists.
PL1759001T3 (en) 2004-04-21 2011-09-30 Alexion Pharma Inc Bone delivery conjugates and method of using same to target proteins to bone
KR101749310B1 (en) 2008-01-24 2017-06-21 에스퍼란스 파마슈티컬스, 인코포레이티드 Lytic domain fusion constructs and methods of making and using same
EP2213686A1 (en) * 2009-01-28 2010-08-04 Externautics S.p.A. Tumor markers and methods of use thereof
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
CN105121472A (en) 2012-10-30 2015-12-02 埃斯佩兰斯医药公司 Antibody/drug conjugates and methods of use
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
MX2017007392A (en) 2014-12-05 2019-01-24 Alexion Pharma Inc Treating seizure with recombinant alkaline phosphatase.
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
CN108350440A (en) 2015-08-17 2018-07-31 阿雷克森制药公司 The manufacture of alkaline phosphate ester
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
CA3019726A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
CA3021644A1 (en) * 2016-05-06 2017-11-09 Phasebio Pharmaceuticals, Inc. Elp fusion proteins for controlled and sustained release
EP3464573A4 (en) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
KR20190129058A (en) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 How to treat hypophosphatase (HPP) in adults and adolescents
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000603A1 (en) * 1992-06-26 1994-01-06 The Trustees Of Princeton University Method for detecting pre-cancerous or cancerous cells using p90 antibodies or probes
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
ES2286843T3 (en) * 1997-01-14 2007-12-01 Human Genome Sciences, Inc. 6 ALPHA AND 6 BETA RECEIVERS OF THE TUMOR NECROSIS FACTOR.
US5885800A (en) * 1997-02-04 1999-03-23 Smithkline Beecham Corporation DNA encoding tumor necrosis related receptor, TR4
AU9013998A (en) * 1997-07-21 1999-02-10 Zymogenetics Inc. Tumor necrosis factor receptor ztnfr-5
PT1015587E (en) * 1997-09-18 2008-07-31 Genentech Inc Dcr3 polypeptide, a tnfr homolog

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001248840B2 (en) * 2000-04-21 2005-06-09 Fuso Pharmaceutical Industries, Ltd. Novel collectins

Also Published As

Publication number Publication date
WO2000053755A2 (en) 2000-09-14
WO2000053755A3 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2212299A (en) Compositions and methods for the treatment of tumor
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
AU6147401A (en) Compositions and methods for the treatment of cancer
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
AU6062900A (en) Substituted indole compounds and their use for the treatment of cancer
IL141426A0 (en) Compositions and methods for the treatment of tumor
IL143212A0 (en) Compositions and methods for the treatment of tumor
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
AU1878201A (en) Composition for the treatment of damaged tissue
AU4228000A (en) Methods and compositions for the treatment and prevention of lung disease
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
AU2001271284A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
AU2001296224A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2566201A (en) Compounds and methods for the treatment of pain
AUPQ367699A0 (en) Treatment of cancer
AU5552400A (en) Treatment of cancer
AU2420101A (en) Method and composition for the treatment of pain
AU4452900A (en) Compositions and methods for the therapy and diagnosis of prostate cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase